![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
IBALIZUMAB SUSCEPTIBILITY IN PATIENT HIV ISOLATES RESISTANT TO ANTIRETROVIRALS
|
|
|
Reported by Jules Levin
CROI 2018 March 4-7 Boston MA
S. WEINHEIMER1, C. MARSOLAIS2, Z. COHEN2, S. LEWIS1
1TaiMed Biologics, Irvine, CA, 2Theratechnologies, Montreal, Canada.
"Patients receiving their current failing ARV therapy, or no therapy, were monitored during a 7-day control period. Thereafter, a loading dose of 2,000 mg of intravenous (IV) IBA was the only ARV agent added to their regimen for 7 days. IBA was continued at doses of 800 mg IV every 2 weeks through 24 weeks on study treatment."
![0307181](../images%20/030718/030618-19/0307181.gif)
![0307182](../images%20/030718/030618-19/0307182.gif)
![0307183](../images%20/030718/030618-19/0307183.gif)
![0307184](../images%20/030718/030618-19/0307184.gif)
![0307185](../images%20/030718/030618-19/0307185.gif)
![0307186](../images%20/030718/030618-19/0307186.gif)
![0307187](../images%20/030718/030618-19/0307187.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|